Effects of Feeding Schedule on the Development of ICU Delirium

April 8, 2024 updated by: Deepali Dixit, Pharm.D., BCPS, BCCCP, FCCM, Rutgers, The State University of New Jersey
This study will investigate if enteric feeding schedules alter the development of delirium in Intensive Care Unit patients who have been placed on mechanical ventilation. Delirium is an altered state of consciousness, which can involve agitation, inattention, and decreased awareness. We will enroll Intensive Care Unit patients who have been placed on a ventilator and are being given tube feedings. We will randomize participants into two groups: one group will receive continuous feedings via feeding tube, and the other group will receive feedings on a schedule to mimic breakfast, lunch, a snack, and dinner. Subjects will be assessed for the development of delirium. Subjects will also be monitored for sleep quality.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Patients will need to have at least 48 hours of enteric feedings to be included, and will be stratified by their APACHE IV score. Patients will be randomized into time restricted feeding vs continuous feeding by investigators, with no change in caloric intake nor nutrient content from orders. Patients will be assessed for delirium using the CAM-ICU (Confusion Assessment Method in the Intensive Care Unit) screening tool every twelve hours. At the time of the CAM ICU assessment, as part of the experimental design, the patient's sleep will be monitored by X8 Sleep Profiler device, placed and secured to their forehead, and the Sleep Profiler device will collect information regarding sleep quality as assessed by relative delta power, relative theta power and relative beta power.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • New Jersey
      • New Brunswick, New Jersey, United States, 08901
        • Recruiting
        • Robert Wood Johnson University Hospital
        • Contact:
          • Deepali Dixit, PharmD
          • Phone Number: 848-445-6825

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 89 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Admitted to the ICU
  • Mechanically ventilated
  • Receiving enteric feedings for at least 48 hours

Exclusion Criteria:

  • Pregnancy
  • Previously diagnosed neurocognitive disorders,
  • Alcohol withdrawal and history of alcohol dependence

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Continuous Feeding
Enteric feeding will be given continuously.
Experimental: Timed Feeding
Enteric feeding will be given four times per day, approximating breakfast, lunch, a snack, and dinner.
All subjects will be given nutrition enterally, corresponding to their calculated nutritional needs.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percent of patients developing delirium.
Time Frame: 48 hours after admission to the ICU.
The development of delirium as measured by the CAM-ICU (Confusion Assessment Method for the ICU) protocol. The percent of patients developing delirium will be assessed in each arm. Delirium will be assessed every 12 hours.
48 hours after admission to the ICU.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in sleep quality assessed using delta power.
Time Frame: Measurement will be made from study enrollment to extubation, up to 1 week.
Change in relative delta power on EEG will be assessed in each arm.
Measurement will be made from study enrollment to extubation, up to 1 week.
Change in sleep quality assessed using theta power.
Time Frame: Measurement will be made from study enrollment to extubation, up to 1 week.
Change in relative theta power on EEG will be assessed in each arm.
Measurement will be made from study enrollment to extubation, up to 1 week.
Change in sleep quality using beta power.
Time Frame: Measurement will be made from study enrollment to extubation, up to 1 week.
Change in relative beta power on EEG will be assessed in each arm.
Measurement will be made from study enrollment to extubation, up to 1 week.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Deepali Dixit, PharmD, Rutgers Ernest Mario School of Pharmacy

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 26, 2021

Primary Completion (Estimated)

April 26, 2024

Study Completion (Estimated)

April 26, 2024

Study Registration Dates

First Submitted

April 23, 2021

First Submitted That Met QC Criteria

April 28, 2021

First Posted (Actual)

May 3, 2021

Study Record Updates

Last Update Posted (Actual)

April 9, 2024

Last Update Submitted That Met QC Criteria

April 8, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on ICU Delirium

Clinical Trials on Enteric feeding

3
Subscribe